240 related articles for article (PubMed ID: 30697907)
1. A Multidisciplinary Approach to Pretransplant and Posttransplant Management of Cystic Fibrosis-Associated Liver Disease.
Freeman AJ; Sellers ZM; Mazariegos G; Kelly A; Saiman L; Mallory G; Ling SC; Narkewicz MR; Leung DH
Liver Transpl; 2019 Apr; 25(4):640-657. PubMed ID: 30697907
[TBL] [Abstract][Full Text] [Related]
2. Analysis of a large cohort of cystic fibrosis patients with severe liver disease indicates lung function decline does not significantly differ from that of the general cystic fibrosis population.
Polineni D; Piccorelli AV; Hannah WB; Dalrymple SN; Pace RG; Durie PR; Ling SC; Knowles MR; Stonebraker JR
PLoS One; 2018; 13(10):e0205257. PubMed ID: 30307979
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of patients with cystic fibrosis undergoing lung transplantation with and without cystic fibrosis-associated liver cirrhosis.
Nash EF; Volling C; Gutierrez CA; Tullis E; Coonar A; McRae K; Keshavjee S; Singer LG; Durie PR; Chaparro C
Clin Transplant; 2012; 26(1):34-41. PubMed ID: 21272072
[TBL] [Abstract][Full Text] [Related]
4. Hepatic Manifestations of Cystic Fibrosis.
Sakiani S; Kleiner DE; Heller T; Koh C
Clin Liver Dis; 2019 May; 23(2):263-277. PubMed ID: 30947876
[TBL] [Abstract][Full Text] [Related]
5. Importance of hepatic fibrosis in cystic fibrosis and the predictive value of liver biopsy.
Lewindon PJ; Shepherd RW; Walsh MJ; Greer RM; Williamson R; Pereira TN; Frawley K; Bell SC; Smith JL; Ramm GA
Hepatology; 2011 Jan; 53(1):193-201. PubMed ID: 21254170
[TBL] [Abstract][Full Text] [Related]
6. Cystic Fibrosis-Associated Liver Disease in Lung Transplant Recipients.
Mallea J; Bolan C; Cortese C; Harnois D
Liver Transpl; 2019 Aug; 25(8):1265-1275. PubMed ID: 31102574
[TBL] [Abstract][Full Text] [Related]
7. Controlled attenuation parameter: A measure of hepatic steatosis in patients with cystic fibrosis.
Bader RM; Jonas MM; Mitchell PD; Wiggins S; Lee CK
J Cyst Fibros; 2019 Mar; 18(2):280-285. PubMed ID: 30509601
[TBL] [Abstract][Full Text] [Related]
8. The natural history of cystic fibrosis liver disease a prospective cohort study.
Rowland M; Drummond J; Connolly L; Daly E; McCormick PA; Bourke B; ;
J Cyst Fibros; 2023 Nov; 22(6):1054-1061. PubMed ID: 37495468
[TBL] [Abstract][Full Text] [Related]
9. Genetic modifiers of liver disease in cystic fibrosis.
Bartlett JR; Friedman KJ; Ling SC; Pace RG; Bell SC; Bourke B; Castaldo G; Castellani C; Cipolli M; Colombo C; Colombo JL; Debray D; Fernandez A; Lacaille F; Macek M; Rowland M; Salvatore F; Taylor CJ; Wainwright C; Wilschanski M; Zemková D; Hannah WB; Phillips MJ; Corey M; Zielenski J; Dorfman R; Wang Y; Zou F; Silverman LM; Drumm ML; Wright FA; Lange EM; Durie PR; Knowles MR;
JAMA; 2009 Sep; 302(10):1076-83. PubMed ID: 19738092
[TBL] [Abstract][Full Text] [Related]
10. Cirrhosis associated with decreased survival and a 10-year lower median age at death of cystic fibrosis patients in the Netherlands.
Pals FH; Verkade HJ; Gulmans VAM; De Koning BAE; Koot BGP; De Meij TGJ; Hendriks DM; Gierenz N; Vreugdenhil ACE; Houwen RHJ; Bodewes FAJA
J Cyst Fibros; 2019 May; 18(3):385-389. PubMed ID: 30558881
[TBL] [Abstract][Full Text] [Related]
11. Liver cirrhosis and portal hypertension in cystic fibrosis.
Efrati O; Barak A; Modan-Moses D; Augarten A; Vilozni D; Katznelson D; Szeinberg A; Yahav J; Bujanover Y
Eur J Gastroenterol Hepatol; 2003 Oct; 15(10):1073-8. PubMed ID: 14501614
[TBL] [Abstract][Full Text] [Related]
12. Outcome of cystic fibrosis-associated liver cirrhosis: management of portal hypertension.
Debray D; Lykavieris P; Gauthier F; Dousset B; Sardet A; Munck A; Laselve H; Bernard O
J Hepatol; 1999 Jul; 31(1):77-83. PubMed ID: 10424286
[TBL] [Abstract][Full Text] [Related]
13. Gamma-glutamyl transpeptidase-to-platelet ratio as a biomarker of liver disease and hepatic fibrosis severity in paediatric Cystic Fibrosis.
Calvopina DA; Lewindon PJ; Ramm LE; Noble C; Hartel GF; Leung DH; Ramm GA
J Cyst Fibros; 2022 Mar; 21(2):236-242. PubMed ID: 34953741
[TBL] [Abstract][Full Text] [Related]
14. Aspartate aminotransferase to platelet ratio and fibrosis-4 as biomarkers in biopsy-validated pediatric cystic fibrosis liver disease.
Leung DH; Khan M; Minard CG; Guffey D; Ramm LE; Clouston AD; Miller G; Lewindon PJ; Shepherd RW; Ramm GA
Hepatology; 2015 Nov; 62(5):1576-83. PubMed ID: 26223427
[TBL] [Abstract][Full Text] [Related]
15. Cystic fibrosis-associated liver disease in children.
Wasuwanich P; Karnsakul W
Minerva Pediatr; 2020 Oct; 72(5):440-447. PubMed ID: 32418413
[TBL] [Abstract][Full Text] [Related]
16. Liver and combined lung and liver transplantation for cystic fibrosis: analysis of the UNOS database.
Arnon R; Annunziato RA; Miloh T; Padilla M; Sogawa H; Batemarco L; Willis A; Suchy F; Kerkar N
Pediatr Transplant; 2011 May; 15(3):254-64. PubMed ID: 21219560
[TBL] [Abstract][Full Text] [Related]
17. Hepatic Steatosis Is Prevalent Following Orthotopic Liver Transplantation in Children With Cystic Fibrosis.
Cortes-Santiago N; Leung DH; Castro E; Finegold M; Wu H; Patel KR
J Pediatr Gastroenterol Nutr; 2019 Jan; 68(1):96-103. PubMed ID: 30234762
[TBL] [Abstract][Full Text] [Related]
18. Advanced but not mild liver disease is a predictor of decreased survival in children with cystic fibrosis, with far greater impact in females: A 27-year real-life cohort study.
Baldissera M; Lewindon PJ; Ramm LE; Hartel GF; Mattiello R; Ramm GA
J Cyst Fibros; 2022 Mar; 21(2):230-235. PubMed ID: 34949555
[TBL] [Abstract][Full Text] [Related]
19. Liver disease in adult patients with cystic fibrosis: a frequent and independent prognostic factor associated with death or lung transplantation.
Chryssostalis A; Hubert D; Coste J; Kanaan R; Burgel PR; Desmazes-Dufeu N; Soubrane O; Dusser D; Sogni P
J Hepatol; 2011 Dec; 55(6):1377-82. PubMed ID: 21703187
[TBL] [Abstract][Full Text] [Related]
20. SERPINA1 Z allele is associated with cystic fibrosis liver disease.
Boëlle PY; Debray D; Guillot L; Corvol H;
Genet Med; 2019 Sep; 21(9):2151-2155. PubMed ID: 30739910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
